Adriana H Tremoulet1, Sonia Jain2, Pei-Ni Jone3, Brookie M Best4, Elizabeth H Duxbury4, Alessandra Franco5, Beth Printz5, Samuel R Dominguez6, Heather Heizer6, Marsha S Anderson6, Mary P Glodé6, Feng He2, Robert L Padilla5, Chisato Shimizu5, Emelia Bainto5, Joan Pancheri5, Harvey J Cohen7, John C Whitin7, Jane C Burns5. 1. Kawasaki Disease Research Center, Department of Pediatrics, University of California San Diego, La Jolla, CA; Rady Children's Hospital-San Diego, San Diego, CA. Electronic address: atremoulet@ucsd.edu. 2. Biostatistics Research Center, Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA. 3. Pediatric Cardiology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO. 4. Kawasaki Disease Research Center, Department of Pediatrics, University of California San Diego, La Jolla, CA; Rady Children's Hospital-San Diego, San Diego, CA; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA. 5. Kawasaki Disease Research Center, Department of Pediatrics, University of California San Diego, La Jolla, CA; Rady Children's Hospital-San Diego, San Diego, CA. 6. Pediatric Infectious Disease, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO. 7. Department of Pediatrics, Stanford University, Stanford, CA.
Abstract
OBJECTIVES: To determine the safety, tolerability, pharmacokinetics, and immunomodulatory effects of a 6-week course of atorvastatin in patients with acute Kawasaki disease with coronary artery (CA) aneurysm (CAA). STUDY DESIGN: This was a Phase I/IIa 2-center dose-escalation study of atorvastatin (0.125-0.75 mg/kg/day) in 34 patients with Kawasaki disease (aged 2-17 years) with echocardiographic evidence of CAA. We measured levels of the brain metabolite 24(S)-hydroxycholesterol (24-OHC), serum lipids, acute-phase reactants, liver enzymes, and creatine phosphokinase; peripheral blood mononuclear cell populations; and CA internal diameter normalized for body surface area before atorvastatin treatment and at 2 and 6 weeks after initiation of atorvastatin treatment. RESULTS: A 6-week course of up to 0.75 mg/kg/day of atorvastatin was well tolerated by the 34 subjects (median age, 5.3 years; IQR, 2.6-6.4 years), with no serious adverse events attributable to the study drug. The areas under the curve for atorvastatin and its metabolite were larger in the study subjects compared with those reported in adults, suggesting a slower rate of metabolism in children. The 24-OHC levels were similar between the atorvastatin-treated subjects and matched controls. CONCLUSIONS: Atorvastatin was safe and well tolerated in our cohort of children with acute Kawasaki disease and CAA. A Phase III efficacy trial is warranted in this patient population, which may benefit from the known anti-inflammatory and immunomodulatory effects of this drug.
OBJECTIVES: To determine the safety, tolerability, pharmacokinetics, and immunomodulatory effects of a 6-week course of atorvastatin in patients with acute Kawasaki disease with coronary artery (CA) aneurysm (CAA). STUDY DESIGN: This was a Phase I/IIa 2-center dose-escalation study of atorvastatin (0.125-0.75 mg/kg/day) in 34 patients with Kawasaki disease (aged 2-17 years) with echocardiographic evidence of CAA. We measured levels of the brain metabolite 24(S)-hydroxycholesterol (24-OHC), serum lipids, acute-phase reactants, liver enzymes, and creatine phosphokinase; peripheral blood mononuclear cell populations; and CA internal diameter normalized for body surface area before atorvastatin treatment and at 2 and 6 weeks after initiation of atorvastatin treatment. RESULTS: A 6-week course of up to 0.75 mg/kg/day of atorvastatin was well tolerated by the 34 subjects (median age, 5.3 years; IQR, 2.6-6.4 years), with no serious adverse events attributable to the study drug. The areas under the curve for atorvastatin and its metabolite were larger in the study subjects compared with those reported in adults, suggesting a slower rate of metabolism in children. The 24-OHC levels were similar between the atorvastatin-treated subjects and matched controls. CONCLUSIONS:Atorvastatin was safe and well tolerated in our cohort of children with acute Kawasaki disease and CAA. A Phase III efficacy trial is warranted in this patient population, which may benefit from the known anti-inflammatory and immunomodulatory effects of this drug.
Authors: Maria Rosa Costanzo; Anne Dipchand; Randall Starling; Allen Anderson; Michael Chan; Shashank Desai; Savitri Fedson; Patrick Fisher; Gonzalo Gonzales-Stawinski; Luigi Martinelli; David McGiffin; Jon Smith; David Taylor; Bruno Meiser; Steven Webber; David Baran; Michael Carboni; Thomas Dengler; David Feldman; Maria Frigerio; Abdallah Kfoury; Daniel Kim; Jon Kobashigawa; Michael Shullo; Josef Stehlik; Jeffrey Teuteberg; Patricia Uber; Andreas Zuckermann; Sharon Hunt; Michael Burch; Geetha Bhat; Charles Canter; Richard Chinnock; Marisa Crespo-Leiro; Reynolds Delgado; Fabienne Dobbels; Kathleen Grady; W Kao; Jaqueline Lamour; Gareth Parry; Jignesh Patel; Daniela Pini; Jeffrey Towbin; Gene Wolfel; Diego Delgado; Howard Eisen; Lee Goldberg; Jeff Hosenpud; Maryl Johnson; Anne Keogh; Clive Lewis; John O'Connell; Joseph Rogers; Heather Ross; Stuart Russell; Johan Vanhaecke Journal: J Heart Lung Transplant Date: 2010-08 Impact factor: 10.247
Authors: Ming He; Zhen Chen; Marcy Martin; Jin Zhang; Panjamaporn Sangwung; Brian Woo; Adriana H Tremoulet; Chisato Shimizu; Mukesh K Jain; Jane C Burns; John Y-J Shyy Journal: Circ Res Date: 2016-12-06 Impact factor: 17.367
Authors: Brian W McCrindle; Elaine M Urbina; Barbara A Dennison; Marc S Jacobson; Julia Steinberger; Albert P Rocchini; Laura L Hayman; Stephen R Daniels Journal: Circulation Date: 2007-03-21 Impact factor: 29.690
Authors: Nagib Dahdah; Samuel C Kung; Kevin G Friedman; Ariane Marelli; John B Gordon; Ermias D Belay; Annette L Baker; Dhruv S Kazi; Patience H White; Adriana H Tremoulet Journal: J Am Heart Assoc Date: 2021-10-11 Impact factor: 5.501
Authors: Stefanie Marek-Iannucci; Asli B Ozdemir; Debbie Moreira; Angela C Gomez; Malcolm Lane; Rebecca A Porritt; Youngho Lee; Kenichi Shimada; Masanori Abe; Aleksandr Stotland; David Zemmour; Sarah Parker; Elsa Sanchez-Lopez; Jennifer Van Eyk; Roberta A Gottlieb; Michael C Fishbein; Michael Karin; Timothy R Crother; Magali Noval Rivas; Moshe Arditi Journal: JCI Insight Date: 2021-09-22